Clinical trials · New York, NY
End Stage Kidney Disease clinical trials in New York
We’re tracking 18 recruiting end stage kidney disease studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06878560RecruitingPhase 1/Phase 2
Pig kidney transplant for kidney failure patients
This trial tests a special pig kidney (10 GE Xenokidney) as a transplant option for people with kidney failure who cannot get a human kidney. It aims to offer a life-saving alternative.
New York, New YorkAges 40–70 - NCT06056102RecruitingPhase 1
CAR-T cell therapy to help highly sensitized kidney transplant patients
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
New York, New YorkAges 18–65 - NCT05786443RecruitingPhase 2
Empagliflozin test in adults on regular dialysis
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
New York, New YorkAges 18 years+ - NCT07224763RecruitingPhase 1/Phase 2
Pig kidney transplant trial for kidney failure patients
This trial tests a genetically modified pig kidney (Thymokidney) for people with end-stage kidney disease who are on dialysis. It aims to see if this new type of transplant is safe and effective for those who cannot get a human kidney.
New York, New YorkAges 40–70 - NCT05832229RecruitingPhase 2
Studying rosuvastatin to slow liver scarring in cirrhosis
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
New York, New YorkAges 18–75 - NCT05312879RecruitingPhase 2/Phase 3
Test drug VX-147 for APOL1-related protein in urine kidney disease
This trial studies whether VX-147 can improve kidney disease caused by an APOL1 gene change, which often leads to protein leaking into the urine. It includes both adults and children and focuses on safety and effectiveness over time.
New York, New YorkAges 10–65 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
New York, New YorkAges 18–75 - NCT04671771Recruiting
Testing a new graft for hemodialysis access in kidney failure
This study tests whether an “AV graft” implant works safely and well for people with end-stage kidney disease who need hemodialysis. It may help your dialysis access last and work better, compared with current expectations for AV grafts.
New York, New YorkAges 18–90 - NCT05828823Recruiting
Two-times-a-week dialysis for new patients
This study tests whether starting dialysis at twice a week, instead of the usual three times, is safe and effective for people who still have some kidney function. If the kidneys still make urine and clear waste, being on dialysis less often may maintain that function longer.
New York, New YorkAges 18 years+ - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
New York, New YorkAges 18–75 - NCT05485961RecruitingPhase 2/Phase 3
Clazakizumab for kidney failure patients on dialysis
This study tests an experimental drug called clazakizumab (CSL300) to see if it can reduce inflammation and lower the risk of heart problems in people with kidney failure who are on dialysis. It may help if you have diabetes or heart disease and have high inflammation levels.
Jersey City, New JerseyAges 18 years+ - NCT06749457RecruitingPhase 1/Phase 2
Study of a new drug for healthy adults and kidney patients on dialysis
This trial tests a new drug called AZD7760 in two groups: healthy adults (Phase I) and adults with end-stage kidney disease who are on hemodialysis through a central venous catheter (Phase IIa). The goal is to see how safe the drug is and how the body processes it. This could lead to a new treatment option for people on dialysis.
Jersey City, New JerseyAges 18–55 - NCT06712654RecruitingPhase 2
Testing AP306 for high phosphate in dialysis patients
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
Ridgewood, New YorkAges 18 years+ - NCT06933472RecruitingPhase 3
Study of a new phosphate binder for dialysis patients
This trial tests a new drug called AP301 to lower high phosphate levels in people on dialysis. It's designed to help control phosphate, which can be hard to manage with diet and current medications.
Ridgewood, New YorkAges 12 years+ - NCT07153939Recruiting
Study of a new device to create dialysis access
This trial tests a new device called the Velocity pAVF System that creates a connection between a vein and artery in your arm for hemodialysis. If you need dialysis now or within the next 6 months, this could be a new option for you.
Staten Island, New YorkAges 18–80 - NCT06001827Recruiting
Study of a wrap to help new dialysis access points heal
This trial tests a special wrap placed around a new arm access point for dialysis (called an AV fistula) to see if it helps the access stay healthy and work better. It is for people who need a new AV fistula for kidney dialysis.
Lake Success, New YorkAges 18 years+ - NCT06613568Recruiting
Testing a new home hemodialysis machine
This study tests a new home hemodialysis machine called the Moda-flx System. If you are on stable dialysis and have a care partner, you and your partner will learn how to use the machine at home, and the trial will see if it can safely and effectively replace your regular dialysis.
New Hyde Park, New YorkAges 18–80 - NCT07217535Recruiting
Studying the genetics of kidney disease
This study collects DNA and health information from people in the U.S. to better understand how genes may affect kidney disease. Your participation could help researchers find new ways to prevent or treat kidney problems.
Piscataway, New JerseyAges 18 years+
Hear when a new End Stage Kidney Disease trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
End Stage Kidney Disease trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting end stage kidney disease studies listed above.
- NYU Langone Health · 4 studies
- Northwell Health · 3 studies
- GSK Investigational Site · 2 studies
- James J. Peters VA Medical Center · 2 studies
- Montefiore Medical Center · 2 studies
- NY Kidney & Hypertension Medicine · 2 studies
- State University of New York Downstate Medical Center · 2 studies
- Albert Einstein College of Medicine
What taking part in a end stage kidney disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting end stage kidney disease studies in New York.
Common questions
- Are there end stage kidney disease clinical trials near New York?
- Yes. We're currently tracking 18 recruiting end stage kidney disease studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a end stage kidney disease study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a end stage kidney disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New end stage kidney disease studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.